The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.4% in the morning session after TD Cowen reiterated a Buy rating and a $65.00 price target on the stock.

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest ...

Bio-Techne Corp, has agreed to an acquisition offer by Germany’s Merck KGaA for about $11.3 billion, the largest M&A deal ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...

The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...

Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the ...

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.